Minerva Neurosciences (NERV) Assets Average (2014 - 2026)
Minerva Neurosciences posted quarterly Assets Average of $96.0 million for Q1 2026, up 174.51% year-on-year from $35.0 million in Q1 2025, and up 52.3% on a QoQ basis from $63.0 million in Q4 2025.
Minerva Neurosciences (NERV) has 13 years of Assets Average data on file, last reported at $96.0 million in Q1 2026.
- For the quarter ending Q1 2026, Assets Average rose 174.51% year-over-year to $96.0 million; the trailing twelve-month figure through Mar 2026 stood at $96.0 million (up 174.51% YoY), and the FY2025 full-year result was $67.6 million, up 43.67% from the prior year.
- Assets Average for Q1 2026 stood at $96.0 million, up from $63.0 million in the prior quarter.
- Across five years, Assets Average topped out at $96.0 million in Q1 2026 and bottomed at $29.3 million in Q3 2025.
- The 5-year median for Assets Average is $57.4 million (2022), against an average of $55.3 million.
- The widest annual swing landed in 2022, when Assets Average slumped 38.53%; it then surged 174.51% in 2026.
- A 5-year view of Assets Average shows it stood at $57.4 million in 2022, then gained by 4.51% to $60.0 million in 2023, then tumbled by 33.39% to $40.0 million in 2024, then jumped by 57.66% to $63.0 million in 2025, then jumped by 52.3% to $96.0 million in 2026.
- The last three Assets Average figures came in at $96.0 million (Q1 2026), $63.0 million (Q4 2025), and $29.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.05 Bn |
| 10 | Minerva Neurosciences | 215.11 Mn | 215.11 Mn | - | 96.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 96.00 Mn |
| Dec 31, 2025 | 63.03 Mn |
| Sep 30, 2025 | 29.26 Mn |
| Jun 30, 2025 | 31.61 Mn |
| Mar 31, 2025 | 34.97 Mn |
| Dec 31, 2024 | 39.98 Mn |
| Sep 30, 2024 | 44.55 Mn |
| Jun 30, 2024 | 48.40 Mn |
| Mar 31, 2024 | 53.71 Mn |
| Dec 31, 2023 | 60.01 Mn |
| Sep 30, 2023 | 65.13 Mn |
| Jun 30, 2023 | 59.37 Mn |
| Mar 31, 2023 | 53.34 Mn |
| Dec 31, 2022 | 57.42 Mn |
| Sep 30, 2022 | 62.36 Mn |
| Jun 30, 2022 | 67.79 Mn |
| Mar 31, 2022 | 73.87 Mn |
| Dec 31, 2021 | 87.34 Mn |
| Sep 30, 2021 | 101.44 Mn |
| Jun 30, 2021 | 108.58 Mn |
| Mar 31, 2021 | 84.73 Mn |
| Dec 31, 2020 | 61.42 Mn |
| Sep 30, 2020 | 65.69 Mn |
| Jun 30, 2020 | 67.48 Mn |
| Mar 31, 2020 | 73.14 Mn |
| Dec 31, 2019 | 94.16 Mn |
| Sep 30, 2019 | 115.55 Mn |
| Jun 30, 2019 | 125.05 Mn |
| Mar 31, 2019 | 134.47 Mn |
| Dec 31, 2018 | 144.83 Mn |
| Sep 30, 2018 | 155.74 Mn |
| Jun 30, 2018 | 167.71 Mn |
| Mar 31, 2018 | 179.08 Mn |
| Dec 31, 2017 | 188.60 Mn |
| Sep 30, 2017 | 160.44 Mn |
| Jun 30, 2017 | 131.34 Mn |
| Mar 31, 2017 | 134.12 Mn |
| Dec 31, 2016 | 137.33 Mn |
| Sep 30, 2016 | 144.11 Mn |
| Jun 30, 2016 | 120.47 Mn |
| Mar 31, 2016 | 88.50 Mn |
| Dec 31, 2015 | 85.95 Mn |
| Sep 30, 2015 | 91.82 Mn |
| Jun 30, 2015 | 98.09 Mn |
| Mar 31, 2015 | 85.15 Mn |
| Dec 31, 2014 | 70.89 Mn |
| Sep 30, 2014 | 63.14 Mn |